PMEL and melanoma: CSPG4/MCSP had previously been identified as a marker of melanoma cells [144,145] and was used in a preceding study to establish an immunoaffinity-based method to isolate melanoma-specific sEVs, which were characterized by enrichment of melanoma-associated antigens (MAAs), such as TYRP2, MelanA, GP100, and VLA4 compared to non-captured sEV [146].